
STATUTORY INSTRUMENTS

2010 No. 551

The Medicines (Products for Human
Use) (Fees) Regulations 2010

PART 15

Consequential Amendments

Amendment of the Medicines for Human Use (Clinical Trials) Regulations 2004

51.—(1) The Medicines for Human Use (Clinical Trials) Regulations 2004⁽¹⁾ are amended as follows.

(2) In regulation 17(2)(b)(ii), for “Medicines (Products for Human Use – Fees) Regulations 1995” substitute “Medicines (Products for Human Use) (Fees) Regulations 2010”.

(3) In regulation 24(10)(2), in the definition of “any relevant fee”, for “Medicines (Products for Human Use – Fees) Regulations 1995” substitute “Medicines (Products for Human Use) (Fees) Regulations 2010”.

(4) In regulation 38(3)(b), for “Medicines (Products for Human Use – Fees) Regulations 1995” substitute “Medicines (Products for Human Use) (Fees) Regulations 2010”.

(5) In regulation 44(8)(3), in the definition of “any relevant fee”, for “Medicines (Products for Human Use – Fees) Regulations 1995” substitute “Medicines (Products for Human Use) (Fees) Regulations 2010”.

(1) [S.I. 2004/1031](#); relevant amendments are made by [S.I. 2006/1928](#).
(2) The definition of “any relevant fee” was inserted by [S.I. 2006/1928](#).
(3) The definition of “any relevant fee” was substituted by [S.I. 2006/1928](#).